Revenue ($USD) : $1,153,545,000
R&D spend : $193,817,000
Employees : 2,900
Fiscal year end : 12/31/2023
CEO : Vladimir Makatsaria

www.livanova.com

Cardiac surgery and neuromodulation device company LivaNova has been under the leadership of Johnson & Johnson veteran Vladimir Makatsaria as CEO since February 2024. He was hires nearly a year after Damien McDonald resigned as CEO following some pipeline disappointments. During that interim period, the company decided to wind down its circulatory support unit to focus on its cardiopulmonary and neuromodulation businesses. –SW